Equities

Wanbury Ltd

WANBURY:NSI

Wanbury Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (INR)259.95
  • Today's Change3.95 / 1.54%
  • Shares traded57.74k
  • 1 Year change+188.83%
  • Beta1.1132
Data delayed at least 15 minutes, as of Nov 08 2024 09:59 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in INRIncome statement in INRView more

Year on year Wanbury Ltd grew revenues 15.21% from 5.00bn to 5.76bn. In addition the company has reduced the cost of goods sold, selling, general and administrative expenses and debt expenses (all as a percent of sales). The company reported positive net income, improving from a loss of 103.96m to a profit of 559.56m.
Gross margin49.35%
Net profit margin9.33%
Operating margin14.28%
Return on assets--
Return on equity--
Return on investment--
More ▼

Cash flow in INRView more

In 2024, Wanbury Ltd increased its cash reserves by 127.54%, or 19.06m. Cash Flow from Financing totalled 145.53m or 2.53% of revenues. In addition the company generated 39.78m in cash from operations while cash used for investing totalled 166.25m.
Cash flow per share19.66
Price/Cash flow per share13.01
Book value per share--
Tangible book value per share--
More ▼

Balance sheet in INRView more

Wanbury Ltd uses little or no debt in its capital structure.
Current ratio--
Quick ratio--
Total debt/total equity--
Total debt/total capital--
More ▼

Growth rates in INR

Year on year, growth in earnings per share excluding extraordinary items increased 631.23%.
EPS growth(5 years)--
EPS (TTM) vs
TTM 1 year ago
3,200.08
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.